Literature DB >> 10982177

Partial COL1A2 gene duplication produces features of osteogenesis imperfecta and Ehlers-Danlos syndrome type VII.

M L Raff1, W J Craigen, L T Smith, D R Keene, P H Byers.   

Abstract

Type I collagen is the most abundant structural protein in the mammalian body. It exists as a heterotrimer of two subunits in the form [alpha1(I)]2alpha2(I). Pathogenic mutations in COL1A1 and COL1A2, the genes that encode the two subunits, cause a range of phenotypes including mild to lethal forms of osteogenesis imperfecta and a restricted set of Ehlers-Danlos syndrome phenotypes. Lethal mutations usually result from missense mutations that disrupt the normal triple helical structure of the molecule. Multi-exon duplication or deletion in type I collagen genes has rarely been observed and has generally resulted in a lethal or severe phenotype. We report a partial duplication in the COLIA2 gene that causes a relatively mild phenotype, despite the addition of 477 amino acids to the triple helical domain of the proalpha2(I) chain. The abnormal molecule is synthesized and secreted by cultured dermal fibroblasts in a normal fashion. Electron microscopy of dermal tissue reveals small but otherwise near normal collagen fibrils. The gene duplication occurred by mitotic sister chromatid exchange in the mother who is mosaic for the duplication allele. Examination of the abnormal sequence suggests a means by which the duplicated molecule could be processed and properly incorporated into mature collagen fibrils.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10982177     DOI: 10.1007/s004390051004

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  6 in total

Review 1.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

2.  Osteogenesis imperfecta type III/Ehlers-Danlos overlap syndrome in a Chinese man.

Authors:  Yanqin Lu; Yanzhou Wang; Frank Rauch; Hu Li; Yao Zhang; Naixiang Zhai; Jian Zhang; Xiuzhi Ren; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2018-02

3.  Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing.

Authors:  Xinping Yang; Jasmin Coulombe-Huntington; Shuli Kang; Gloria M Sheynkman; Tong Hao; Aaron Richardson; Song Sun; Fan Yang; Yun A Shen; Ryan R Murray; Kerstin Spirohn; Bridget E Begg; Miquel Duran-Frigola; Andrew MacWilliams; Samuel J Pevzner; Quan Zhong; Shelly A Trigg; Stanley Tam; Lila Ghamsari; Nidhi Sahni; Song Yi; Maria D Rodriguez; Dawit Balcha; Guihong Tan; Michael Costanzo; Brenda Andrews; Charles Boone; Xianghong J Zhou; Kourosh Salehi-Ashtiani; Benoit Charloteaux; Alyce A Chen; Michael A Calderwood; Patrick Aloy; Frederick P Roth; David E Hill; Lilia M Iakoucheva; Yu Xia; Marc Vidal
Journal:  Cell       Date:  2016-02-11       Impact factor: 41.582

Review 4.  Osteogenesis Imperfecta/Ehlers-Danlos Overlap Syndrome and Neuroblastoma-Case Report and Review of Literature.

Authors:  Letteria Anna Morabito; Anna Elsa Maria Allegri; Anna Paola Capra; Mario Capasso; Valeria Capra; Alberto Garaventa; Mohamad Maghnie; Silvana Briuglia; Malgorzata Gabriela Wasniewska
Journal:  Genes (Basel)       Date:  2022-03-25       Impact factor: 4.141

5.  A novel mutation in COL1A2 leads to osteogenesis imperfecta/Ehlers-Danlos overlap syndrome with brachydactyly.

Authors:  Thunyaporn Budsamongkol; Narin Intarak; Thanakorn Theerapanon; Somchai Yodsanga; Thantrira Porntaveetus; Vorasuk Shotelersuk
Journal:  Genes Dis       Date:  2019-03-16

6.  Helical mutations in type I collagen that affect the processing of the amino-propeptide result in an Osteogenesis Imperfecta/Ehlers-Danlos Syndrome overlap syndrome.

Authors:  Fransiska Malfait; Sofie Symoens; Nathalie Goemans; Yolanda Gyftodimou; Eva Holmberg; Vanesa López-González; Geert Mortier; Sheela Nampoothiri; Michael Bjorn Petersen; Anne De Paepe
Journal:  Orphanet J Rare Dis       Date:  2013-05-21       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.